Technology | Population Health | April 03, 2015

PatientPoint Population Health Management Application Receives Meaningful Use Certification

Software provides automated outreach from physicians to patients

April 3, 2015 — PatientPoint announced that PatientPoint Outreach 3.2 is now certified for Meaningful Use in an ambulatory setting. The software is also compliant with the Office of the National Coordinator (ONC) 2014 Edition criteria for certified electronic health record technology (CEHRT).

The ONC 2014 Edition criteria supports both Stage 1 and Stage 2 Meaningful Use measures that are required to qualify eligible providers for funding under the American Recovery and Reinvestment Act (ARRA).

PatientPoint Outreach 3.2 provides trusted and secure communications on behalf of the physician, and is highly customizable to a provider’s goals. By helping to manage patient adherence and follow-up, it can play a key role in improving clinical outcomes throughout the care continuum.

Driven by a population health analytics engine, the software provides automated outreach by email, text and interactive voice response (IVR), depending on the patient's stated preference. Eligible providers can submit against the Stage 1 and Stage 2 criteria for patient list creation and patient reminders.

PatientPoint Outreach 3.2 was certified by the Certification Commission for Health Information Technology (CCHIT) in accordance with the applicable Eligible Provider certification criteria adopted by the Secretary of Health and Human Services. PatientPoint certification (#IG-3251-15-0016) meets the following criteria:

  • 170.314(a)(14) Patient List Creation and Reminders
  • 170.314(g)(2) Automated Measures
  • 170.314(g)(4) Quality Management System

 

The application was certified by Infogard, an Accredited Testing Laboratory (NVLAP Lab Code: 100432-0) and ONC-Authorized Certification Body to test and certify Electronic Health Record (EHR) products for the ONC HIT Certification Program. InfoGard provides information technology services for organizations within the healthcare, financial, and federally mandated markets.

For more information: www.patientpoint.com

Related Content

New Target for Treating Heart Failure Identified by Penn Medicine Researchers

Microtubules in heart cells from a healthy patient (left) and from a patient with heart failure. The dense network of detyrosinated microtubules impedes the motion of the failing heart cell during the heart beat. Credit: Ben Prosser lab, Perelman School of Medicine, University of Pennsylvania

News | Heart Failure | June 25, 2018
New research finds changes in cellular struts called microtubules (MT) can affect the stiffness of diseased human heart...
Gencaro Does Not Reduce Atrial Fibrillation Risk in Heart Failure Patients
News | Heart Failure | May 30, 2018
Data from the GENETIC-AF trial was presented in a “Late Breaking Clinical Trials” oral presentation at the European...
Cardiac Contractility Modulation Safe and Effective as Heart Failure Treatment

Image courtesy of Impulse Dynamics

News | Heart Failure | May 18, 2018
In a new study, cardiac contractility modulation (CCM) therapy was confirmed to significantly improve exercise...
V-Wave Closes $70M Financing to Support Pivotal Study of Heart Failure Therapy
News | Heart Failure | May 16, 2018
Israel-based V-Wave Ltd. recently closed a $70 million Series C financing for its proprietary, minimally invasive...
News | Heart Failure | May 14, 2018
Ancora Heart Inc. announced the expansion of the company’s U.S. feasibility study to evaluate the investigational...
Protein Clumping May Contribute to Heart Failure Development

A PET scan detects clumping proteins in rat hearts (top). The enlarged heart (right) is one with heart failure. Other PET scans showing blood flow in the rat hearts (bottom) show that the protein clumps aren't due to circulation problems. Image courtesy of Circulation Research, May 11, 2018.

News | Heart Failure | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
Minnesota Living With Heart Failure Questionnaire Qualified for FDA Medical Device Development Tools Program

The CORolla device from Israel-based CorAssist is one example of new devices being manufactured and tested to treat heart failure. The efficacy of this and other new devices under development can now be assessed with the Minnesota Living With Heart Failure Questionnaire. 

Technology | Heart Failure | May 07, 2018
The U.S. Food and Drug Administration (FDA) has qualified the Minnesota Living with Heart Failure Questionnaire from...
Nation's First Heart Failure and Arrhythmia Center Opening in Ohio

Image courtesy of The Ohio State University

News | Heart Failure | April 04, 2018
The Ohio State University Wexner Medical Center will establish the nation’s first center dedicated to treating those...
Abbott Initiates GUIDE-HF Trial for Improved Outcomes With CardioMEMS Monitor
News | Heart Failure | March 29, 2018
Abbott announced the company has initiated the landmark GUIDE-HF clinical trial using the CardioMEMS HF System. The...
Overlay Init